Related Experiment Video
Updated: Sep 4, 2025
06:24
Preparation of Nanoparticles for ToF-SIMS and XPS Analysis
Published on: September 13, 2020
8.2K
[Effects of shell composition in shell-core structured nanoparticles on oral physiological barrier and
Hai-Zhen Chen1, Jiang-Pei Shi1, Xiao-Yan Gu1
1School of Pharmacy, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
Summary
Shell-core nanoparticles with different shell compositions were developed to enhance oral drug delivery. Lipid-shelled nanoparticles (SLB-LPNs) showed better mucus penetration, while polymer-shelled nanoparticles (SLB-FPNs) significantly improved oral bioavailability.
Area of Science:
- Nanotechnology
- Materials Science
- Pharmacology
Background:
- Improving oral bioavailability of drugs, especially from traditional Chinese medicine, remains a challenge.
- Nanocarriers offer a promising strategy to overcome physiological barriers in the gastrointestinal tract.
- Understanding the impact of nanocarrier shell composition is crucial for effective oral drug delivery.
Purpose of the Study:
- To prepare and characterize shell-core nanoparticles with varying shell compositions (mixed lipids vs. polymer F127).
- To investigate the influence of shell composition on overcoming gastrointestinal mucus and intestinal epithelial barriers.
- To evaluate the effect of different shell compositions on the oral bioavailability of Silibinin (SLB).
Main Methods:
- Modified nanoprecipitation method used to synthesize Silibinin-loaded nanoparticles (SLB-LPNs and SLB-FPNs).
- Characterization using Transmission Electron Microscopy (TEM) and particle size/Zeta potential analysis.
- Evaluation of mucus and epithelial barrier penetration via cellular internalization kinetics assays.
- In vivo pharmacokinetic studies in rats to determine relative oral bioavailability.
Main Results:
- Both SLB-LPNs and SLB-FPNs exhibited spherical core-shell structures with sizes around 95 nm.
- SLB-LPNs demonstrated superior cell internalization rates, indicating better mucus penetration.
- SLB-FPNs achieved a significantly higher relative oral bioavailability (923.31%) compared to SLB-LPNs (400.37%) and the drug suspension.
Conclusions:
- Nanoparticle shell composition critically affects their ability to overcome oral physiological barriers.
- Shell-core nanoparticles are effective nanocarriers for enhancing oral drug delivery.
- Polymer F127-shelled nanoparticles show significant potential for improving the oral bioavailability of poorly soluble drugs like Silibinin.
Related Concept Videos
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
258
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
258
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
992
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
992
01:21Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
1.9K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
1.9K
01:22Factors Influencing Drug Absorption: Physicochemical Parameters
414
The physicochemical characteristics of drugs play a crucial role in formulating stable and bioavailable drug products. The solubility of a drug, governed by the varying pH along the GI tract and its dissociation constant (pKa), is pivotal in determining its ionization state and absorption rate. Notably, weak acids and bases remain unionized and are absorbed more rapidly.
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
414
01:23Factors Influencing Bioavailability: First-Pass Elimination
6.8K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.8K
01:24Factors Influencing Drug Absorption: Presystemic Elimination
319
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
319